Clinical Trial Update: Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating inhaled treprostinil delivered by Tyvaso nebulizer for COPD patients with hypoxemia; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Treprostinil (Tyvaso) (treprostinil)

Snippet

Sponsor: Bastiaan Driehuys | Conditions: COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia | Phase 2 | Status: RECRUITING